The structural basis for imatinib resistance in chronic myeloid leukaemia (CML) involves the emergence of imatinib-resistant BCR-ABL point mutations; mutations are usually those that impair drug ...
Chronic myelogenous leukaemia (CML) results from the neoplastic transformation of a haematopoietic stem cell. Clinical and laboratory studies indicate that the fusion protein BCR–ABL is essential for ...